Additionally, ddBCMA, featuring a smaller-sized scFv consisting of 73 amino acids (NCT04155749), anti-BCMA VHH antigen binding domain (NCT03664661, NCT03661554), and anti-BCMA VH (engineered human antibody fragment, consisting of the variable domain of the heavy chain) (NCT03602612) have demonstrated the potential to decrease immunogenicity and achieve high response rates in patients with R/R MM [65, 193] (Table 3). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.